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Abstract
Purpose—Survivorship care plans (SCP) are recommended for all cancer patients and could be 
especially useful to survivors 65 years and over (“older”). This study examined receipt of SCPs 
among older breast cancer survivors and whether SCPs were associated with improved patient-
reported outcomes.
Methods—Three hundred and twenty-eight older women diagnosed with invasive, nonmetastatic 
breast cancer between 2007–2011 were recruited from 78 cooperative-group sites. Participants 
completed telephone interviews at baseline and 1-year posttreatment. Regression analyses 
examined SCP receipt (yes/no) and functioning (EORTC-QLQ-C30), cancer worry, and 
experiences of survivorship care (care coordination, knowledge).
Results—Only 35 % of women received SCPs. For each 1-year increase in age, there was a 5 % 
lower odds of receiving an SCP (odds ratio (OR)=0.94, 95 % confidence interval (CI) 0.91–0.98, 
p=0.007). Besides age, no other factor predicted SCPs. SCP receipt was associated with greater 
knowledge and understanding of requisite follow-up care (p<0.05); however, functioning was not 
significantly different among those with vs. without SCPs.
Conclusions—Receipt of care plans was limited. SCPs improved understanding of breast cancer 
follow-up care among older survivors, but did not impact functioning one year post-treatment.
Implications for Cancer Survivors—To impact functioning and salient needs of the growing 
cohort of older survivors, survivorship care plans likely should be tailored to geriatric-specific 
Faul et al. Page 2













issues. To improve functioning, SCP content should expand to include exercise, nutrition, 
polypharmacy, social support and management of symptom burden from cancer, and other 
comorbid conditions. To improve follow-up care for cancer survivors, SCPs should delineate 
shared care roles between oncology and primary care in managing recurrence surveillance, 
screening, and cancer sequelae.
Keywords
Survivorship care plan; Breast cancer; Cancer survivors; Older adults; Cancer survivorship and 
aging
Introduction
Women 65 years and older (“older”) constitute 55 % of the three million U.S. breast cancer 
survivors, and will account for a greater absolute number and proportion of survivors with 
“the graying of America” [1, 2]. This older survivor population often has age-related 
declines in functioning and reserve, increasing levels of comorbid illness, and diminished 
social and economic resources [3–6].
These forces of aging can pose unique challenges for survivorship care, including the need 
to monitor adjuvant hormonal therapy, manage multiple symptoms and medications, and 
coordinate care delivery by multiple physicians [7–10]. Survivorship care can be further 
complicated if older patients are confused about their cancer treatment history [11], 
recommended follow-up care [8, 12], or how to manage their multiple illnesses [13]. Older 
patients may also misattribute modifiable symptoms to “normal aging” or believe that their 
symptoms are not treatable, leading to under-reporting during follow-up visits [14–17].
To improve post-treatment cancer care, the Institute of Medicine recommends providing 
survivorship care plans, and this recommendation was formally incorporated into oncology 
practice guidelines in 2007 [18–23]. The expectation was that care plans would enhance 
survivorship experiences and translate into improved functioning and survival [18, 20, 24, 
25]. While dissemination has been slow [26–28], emerging data suggests that care plans may 
decrease cancer worry [29], enhance understanding of care coordination [30, 31], increase 
confidence in communicating with providers [31], and improve adherence to late effects 
surveillance [32]. However, there is little data regarding the effectiveness of care plans for 
improving functioning [33], and no data on their use in older populations, a group where 
functioning is an especially important outcome [34].
To fill this gap, we analyzed data from a national prospective cohort of older breast cancer 
patients to evaluate the use and impact of survivorship care plans on patient-reported 
outcomes one-year postactive treatment. After describing correlates of care plan receipt, we 
test the hypothesis that older women who received plans (vs. not) would report better 
experiences of survivorship care, controlling for covariates. Further, we postulated that older 
women with care plans would report better functioning and less worry than women without 
plans, controlling for age and prediagnosis functioning. These associations were also 
examined among different subgroups based on age, education, and social support. Finally, 
we conducted exploratory analyses to assess whether survivors’ experiences of care were 
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associated with functioning. Results of this study are intended to contribute to the growing 
literature on survivorship care plans, evaluate their benefits among older breast cancer 
survivors, and guide future interventions to refine care plans for the growing older 
survivorship population.
Methods
Study design and data collection
This report is a secondary analysis of data from a larger longitudinal cohort study examining 
chemotherapy patterns and outcomes among older women at 78 hospitals/practices affiliated 
with Cancer and Leukemia Group B (CALGB) protocol #369901, presently part of the 
Alliance for Clinical Trials in Oncology [35, 36]. The protocol met HIPAA standards and 
was approved by CALGB, NCI, and institutional review boards at all sites. Clinical research 
associates (CRAs) ascertained patients, confirmed eligibility, and upon physician approval, 
obtained consent. Registration was managed by the CALGB Statistical Center. Oncologists 
completed a one-time mail survey, and clinical data were obtained via medical chart 
abstraction. Participants in the cohort were assessed via structured telephone interviews at 
baseline, 6 months, 12-months postbaseline, 24-months postbaseline, and then annually for 
up to 7 years. This secondary analysis focused on outcomes at 24-months, as this follow-up 
timepoint roughly corresponds to one year after active treatment for breast cancer. Active 
treatment for breast cancer comprised surgery, chemotherapy, and radiation, but excluded 
hormonal therapy.
Setting and population
Participants were enrolled between January 2004 and April 2011. To enroll in the study, one 
must have been (a) female with newly diagnosed with invasive nonmetastatic breast cancer 
(tumors ≥1 cm, stage I–III), b) at least 65 years old at the time of breast cancer diagnosis, (c) 
English- or Spanish-speaking, and (d) within 20 weeks of their last definitive surgery. 
Among the 1,703 women registered, 91 % were eligible to complete the baseline interview 
(Fig. 1). One hundred and forty-five women were ineligible for baseline interviews due to 
failing the cognitive screen [37], dying prior to interview, or being found stage ineligible. 
The larger cohort sample included 1,558 participants, 1,288 of whom completed a baseline 
interview. Among these 1,288 participants, women were excluded from this secondary 
analysis due to the following: study enrollment before 2007 when care plans were first 
recommended [19] and enrollment in late 2008 before questions regarding care planning 
were added to interviews (n= 701). Additionally, we excluded 106 women who experienced 
breast cancer recurrence between baseline and 24-month follow-up due to re-initiation of 
active breast cancer treatment.
From this target sample, 328 women (68 %) completed 24-month interviews (one year 
postactive treatment), thus forming the final analytic sample for this secondary analysis. 
There were no differences in sociodemographic or clinical factors between the final analytic 
sample and the 153 women excluded due to missing data. Additionally, the 328 women in 
the analytic sample were similar to the overall cohort, except for having earlier stage 
(p=0.04, due to the exclusion of recurrences), and having received treatment in a community 
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setting (vs. comprehensive cancer center, p=0.004). These two factors were not controlled 
for as covariates in multivariate analyses, given that “site of treatment” did not affect the 
results when included in the model and “earlier stage” was anticipated given our deliberate 
exclusion of women with recurrence from the final analytic sample.
Measures
Measures were guided by the care planning research paradigm described by Parry and 
colleagues [33]. After examining correlates of receipt of a survivorship care plan (yes/no), 
this variable was the primary factor used to assess associations with study outcomes. 
Women were asked if they “were ever given a written breast cancer care plan by the doctors 
you have seen when you finished your treatment? This plan might include a summary of 
your breast cancer and all the treatments you got, and suggestions for what things you or 
your doctors should do in the next year.”
Outcomes
We examined the association of care plans with two patient-reported outcomes: measures of 
survivorship care experiences (patient-oncologist communication, care coordination, self-
efficacy in communicating with physicians, and knowledge of survivorship care) and 
functioning (physical, emotional, and role). Cancer worry was a secondary outcome.
Communication with oncologists was adapted from the five-item scale from the Primary 
Care Assessment Survey (PCAS), and assesses thoroughness of oncologists’ questions about 
health concerns and clarity of instructions regarding when to seek additional care [38]. 
Scores range from 0–100 (Cronbach’s=0.97), but given that observed scores were skewed 
toward excellent communication, scores were categorized into “high” vs. “low” based on the 
sample median.
Self-efficacy in communicating with physicians (communication self-efficacy) was 
measured by the Perceived Efficacy in Patient-Physician Interactions scale [39]. This 10-
item scale assesses patients’ confidence in effectively communicating their needs and health 
concerns to providers, with scores ranging from 10–50 (Cronbach’s=0.90). Scores were 
categorized into “high” vs. “low” based on the sample median since there were ceiling 
effects.
Perception of care coordination was assessed using one item from the Picker adult in-patient 
questionnaire [40, 41] adapted for cancer survivors. The item asked the survivor to rate the 
degree to which “doctors coordinated her care so that each physician knows what s/he is 
responsible for” where responses ranged from “very coordinated” to “very uncoordinated” 
on a 5-point Likert scale. Based on prior research, responses were grouped into “very 
coordinated” vs. all other responses [26, 42, 43].
Understanding of breast cancer survivorship care was assessed by a single 4-point Likert-
scaled item and dichotomized as “excellent” vs. “less than excellent” [26, 42, 43]. One 
Picker [40, 44] item was adapted for survivors in order to assess having knowledge of the 
next steps in cancer follow-up care (“always” vs. “less than always”) [26, 42, 43].
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Functional outcomes were assessed by the European Organization for Research and 
Treatment questionnaire (QLQ-C30), initially developed to assess functioning and quality of 
life outcomes in cancer populations [45–49]. Three QLQ-C30 subscales, physical 
functioning (Cronbach’s=0.62), emotional functioning (Cronbach’s=0.76), and role 
functioning (Cronbach’s=0.87), were used; higher scores represent better functioning [45–
49].
Cancer worry was assessed by four items from the Cancer Rehabilitation Evaluation System 
(CARES) (Cronbach’s= 0.77) [50]. Lower scores represent less worry.
Controlling variables
Socio-demographic, clinical, and physician measures were included in these analyses as 
correlates of receiving a care plan and as potential controlling variables for assessment of 
outcomes. Socio-demographic factors include age, race, marital status, type of health 
insurance, education, and year of enrollment. Clinical factors include stage, estrogen 
receptor status, time since diagnosis, and treatment (surgery, chemotherapy); data on 
radiotherapy were not collected. Comorbid illness was assessed by the 16-item Physical 
Health scale of the Older Americans Resources and Services Multidimensional Functional 
Assessment [51]. Pre-cancer functioning were measured using the physical 
(Cronbach’s=0.94, PCS) and mental (Cronbach’s=0.97, MCS) component summary scores 
from Medical Outcomes Survey SF-12; prior role function was measured using a single item 
[52, 53]. Oncologist factors included gender, years since medical school graduation, practice 
setting, and patient volume for breast cancer and for patients 65 and older (high vs. low 
based on sample median).
Statistical analysis
We used t tests and X2 tests to determine differences between women who received care 
plans versus those who did not with respect to socio-demographic, clinical, and physician 
factors. Next, univariate and logistic regression analyses tested for associations of 
survivorship care planning and individual measures of experiences of survivorship care. 
Variables related at p≤0.05 in univariate analysis to both survivorship care plans and 
experiences of care were considered for inclusion in the regression model. Backward 
elimination was then used to select the final model.
Separate linear regression models were used to examine associations between care plans and 
the three functional outcomes and cancer worry, controlling for age and pre-cancer 
functioning, a priori covariates. Additionally, in exploratory analyses, we used linear 
regression models to examine relationships between care plans and functioning among 
subgroups based on age, education, and social support. Additional exploratory analyses of 
the associations between functioning and experiences of survivorship care followed similar 
methodology. The latter were examined to suggest potential pathways of the effect of 
survivorship care plans. Hosmer-Lemeshow (H-L) and R2 statistics were used to assess 
model fit for logistic and linear regressions, respectively.
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Since this was an unplanned analysis, we also estimated post hoc power to detect a 
relationship between survivorship care plans and our primary outcome—functioning. Given 
the sample size, the study had more than 80 % power (two-sided, p=0.05) to detect a 
clinically meaningful difference of 8–10 points on all three functional outcomes [54], 
representing approximately 1 standard deviation on the EORTC [45–49], between women 
who received a care plan vs. those who did not. Power to detect a smaller effect (4-point 
difference or a 0.5 standard deviation) was lower at 34, 63, and 39 % for physical, 
emotional, and role function scales, respectively. We did not consider correlation of care 
plans within site since results were largely null; correction for intra-class correlations should 
only have further decreased significance and power. Data were analyzed with SAS v.9.2 
software (SAS Institute Inc., Cary, NC). Results analyzed were available in the study 
database as of November 6, 2013.
Results
The older survivors included in this analysis were, on average, 72.8 years old (Table 1). 
Most women had ER-positive, node negative breast cancers, and 39.8 % had received 
adjuvant chemotherapy. Women reported physical (mean=51.3± 7.9SD) and emotional 
(mean=56.7±5.4SD) function prior to cancer diagnosis, comparable to population norms 
(mean=50±10SD).
Use of care plans increased from 20 to 37 % in the study period (p value for trend=0.10), but 
overall, only an average of 35 % of older women reported ever receiving a plan (Table 1). 
Women who received plans were younger than those who did not (p=0.006) and more likely 
to be married (p=0.02). Receipt of a care plan was not related to any other socio-
demographic, clinical, or physician-related factors, including receipt of chemotherapy. Only 
age remained significantly related to care plans in multivariate analyses, where the odds of 
receiving a survivorship care plan decreased by 5 % for each one-year increase in age 
(OR=0.94, 95 % CI 0.91–0.98, p=0.007).
Women who received a care plan tended to report better experiences of survivorship care 
than those who did not receive plans (Table 2). Specifically, those who received care plans 
(vs. not) had higher adjusted odds of reporting an excellent (vs. less) understanding of 
follow-up care (aOR 1.73, 95 % CI 1.08–2.9, p=0.02) and greater knowledge of next steps in 
cancer care (aOR 1.72, 95 % CI 1.03–2.9, p=0.04), controlling for covariates. Women who 
received care plans tended to also report higher (vs. lower) self-efficacy in communicating 
with their oncologists, compared to women without care plans (aOR 1.42, 95 % CI 0.92–
2.35, p=0.11). Cancer worry and physical, social, and role functioning did not significantly 
differ among older women with vs. without care plans at one-year post-treatment (Table 3). 
No association was found between care plan receipt and functioning in any subgroups (e.g., 
based on age, education, social support; data not shown).
Finally, we conducted separate linear regression analyses to explore potential relationships 
between functioning and experiences of survivorship care. Each functional domain was 
significantly associated with two or more care factors. For instance, mean physical function 
among women reporting low communication with their oncologists (76.6±1.9SD) was 
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nearly 7 points below that of women with higher communication (83.2±1.9SD), p=0.02 
(data not shown), where an 8-point difference is considered clinically meaningful.
Discussion
This is the first report of the correlates of survivorship care plan receipt and relationships 
between care plans and functional outcomes in older breast cancer patients. Only about one-
third of older women reported receipt of a care plan and rates decreased with advancing age. 
While care plans were associated with better survivorship care experiences, they were not 
related to outcomes of importance to older indiviuals one year after active treatment, 
including physical, emotional, and role functioning, nor did they diminish worry about 
cancer.
Very few older women in our sample received a survivorship care plan. This result is similar 
to that seen nationally [19, 26–28]. Forsythe noted that only 20 % of oncologists reported 
always providing care plans [26]. In our older cohort, rates rose from 20 % in 2007 to about 
37 % by 2011. Low rates of care plans in an older patient population is of specific concern 
since this is a group where coordination of care, recognition of symptoms related to late 
effects of cancer care, and distinguishing these symptoms from those attributable to other 
comorbid illnesses are especially important in improving functioning [34, 55]. Notably, 
women who underwent chemotherapy were no more likely to receive care plans, despite 
their heightened risk of heart failure and other treatment-related late effects [56].
The original development of survivorship care plan recommendations was motivated by 
concerns that many cancer patients reported confusion regarding their follow-up care [8, 11, 
12]. Care coordination and communication have recently been reemphasized as important 
goals of care plans [33]. Our results indicate that care plans have realized the goal of 
enhanced understanding of cancer survivorship care in an older patient population. In 
younger populations, care plans have improved survivors’ knowledge of requisite 
surveillance [32], the provider responsible for their follow-up care [30], and awareness of 
the need for survivorship care [32]. If confirmed, the trends toward relationships between 
experiences of survivorship care and functioning in our exploratory analysis suggest that 
patient-oncologist communication about function may be one pathway whereby care plans 
could potentially affect outcomes important to older survivors. Increased knowledge of 
recommended cancer follow-up care could also enhance adherence to long-term hormonal 
therapy regimens, surveillance for symptoms of recurrence, and screening for new primary 
cancers. While we did not have data to measure these outcomes, evaluation of the ability of 
care plans to impact these additional care components should be a high priority.
Our finding that care plans did not affect the functioning of older women is not surprising 
since most plans focus on treatment summaries and recommended surveillance [26–28], but 
do not include instructions directed specifically at improving functioning [57]. This null 
result is also consistent with two prior randomized controlled trials [29, 30]. For instance, 
Grunfeld and colleagues found that a care plan intervention for younger breast cancer 
survivors did not improve physical functioning, mental well-being, or cancer-related distress 
12-months postintervention [30, 58]. Hershman and colleagues replicated these null results 
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in a small trial of survivors predominately under age 65 [29]. The intervention in these 
negative studies was a single, brief nurse-led session reviewing the care plan. Juxtaposed 
against the null results are findings that cancer patients are more satisfied with information 
received during treatment than in survivorship [59, 60] and that patients like survivorship 
care plans but view them as too technical, incomplete, and somewhat limited in scope 
regarding recommendations for health promotion and prevention [8, 61, 62]. Taken together, 
these results suggest that a priority for future research is to create and test geriatric-centered 
care plans specifically targeting late effects, comorbidities, and other symptoms that affect 
the functioning of older adults [8, 34, 52, 57, 63]. Plans may also need to include explicit 
guidance on methods to maintain and enhance functioning, such as being physically active 
and communicating symptoms to providers.
Strengths of this study include the unique focus on a large sample of older breast cancer 
survivors. However, there are several caveats that should be considered in evaluating our 
results. First, we did not have data on the delivery mode and content of survivorship care 
plans. A related concern is that we relied on self-report of care plan receipt, and as such, 
misclassification was possible. If non-systematic, this could have biased toward the 
observed null result. However, we have no data to determine if misclassification of care 
plans existed. Next, our sample was relatively healthy with limited variability in baseline 
functioning, so that our measures may not have been sensitive enough to capture small 
differences [45, 46]. However, we did have power to detect minimally clinically meaningful 
changes in function [54]. Another limitation of this analysis is that our sample included a 
significant proportion of well-educated survivors treated in cooperative group settings, 
which limits generalizability. Additionally, it is difficult to estimate the impact of loss to 
follow-up in the subsample. However, the women in the analysis were similar to those 
enrolled but lost to follow-up, decreasing the probability of systematic biases affecting 
results.
Overall, the results of this study suggest that while care plans may be having the intended 
positive effect on experiences of survivorship care for older breast cancer patients, the 
promise of benefits in terms of functioning has yet to be realized. However, care plans 
continue to be promoted to improve the quality of survivorship care in the absence of a 
strong empirical evidence base [20, 21, 33] and will soon be required for accreditation by 
the American College of Surgeons Commission on Cancer [20]. Given the projected 
dramatic increases in the number of older cancer survivors, additional research developing 
and testing geriatric-specific survivorship care plans is urgently needed to provide the 
knowledge base to meet the health needs and maximize functioning of this growing 
population.
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Consort diagram for sample selection of older breast cancer patients and survivorship care 
planning. * a total of 1,703 participants registered to the study. This is a correction from a 
2012 publication indicating 1,704 participants [36]. A duplicate entry for one participant 
was deleted. ** 272 participants were missing a response to the item regarding receipt of a 
survivorship care plan because this item was only added to surveys mid-study in late 2008
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